Haptoglobin, hemopexin, and related defense pathwaysâ€”basic science, clinical perspectives, and drug development by Dominik J. Schaer et al.
REVIEW ARTICLE
published: 28 October 2014
doi: 10.3389/fphys.2014.00415
Haptoglobin, hemopexin, and related defense
pathways—basic science, clinical perspectives, and drug
development
Dominik J. Schaer1*, Francesca Vinchi2, Giada Ingoglia2, Emanuela Tolosano2 and Paul W. Buehler3†
1 Division of Internal Medicine, University of Zurich, Zurich, Switzerland
2 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
3 Division of Hematology, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda,
MD, USA
Edited by:
Magnus Gram, Lund University,
Sweden
Reviewed by:
Sruti Shiva, University of Pittsburgh,
USA
Jeak Ling Ding, National University
of Singapore, Singapore
Joseph M. Rifkind, National Institute
on Aging, USA
Soren Kragh Moestrup, Aarhus
University, Denmark
*Correspondence:
Dominik J. Schaer, Division of
Internal Medicine, University
Hospital, Ramistrasse 100,
Zurich CH-8091, Switzerland
e-mail: dominik.schaer@usz.ch
†The findings and conclusions in
this article have not been formally
disseminated by the Food and Drug
Administration and should not be
construed to represent any Agency
determination or policy.
Hemolysis, which occurs in many disease states, can trigger a diverse pathophysiologic
cascade that is related to the specific biochemical activities of free Hb and its porphyrin
component heme. Normal erythropoiesis and concomitant removal of senescent red
blood cells (RBC) from the circulation occurs at rates of approximately 2 × 106
RBCs/second. Within this physiologic range of RBC turnover, a small fraction of
hemoglobin (Hb) is released into plasma as free extracellular Hb. In humans, there is
an efficient multicomponent system of Hb sequestration, oxidative neutralization and
clearance. Haptoglobin (Hp) is the primary Hb-binding protein in human plasma, which
attenuates the adverse biochemical and physiologic effects of extracellular Hb. The cellular
receptor target of Hp is the monocyte/macrophage scavenger receptor, CD163. Following
Hb-Hp binding to CD163, cellular internalization of the complex leads to globin and heme
metabolism, which is followed by adaptive changes in antioxidant and iron metabolism
pathways and macrophage phenotype polarization. When Hb is released from RBCs
within the physiologic range of Hp, the potential deleterious effects of Hb are prevented.
However, during hyper-hemolytic conditions or with chronic hemolysis, Hp is depleted and
Hb readily distributes to tissues where it might be exposed to oxidative conditions. In such
conditions, heme can be released from ferric Hb. The free heme can then accelerate tissue
damage by promoting peroxidative reactions and activation of inflammatory cascades.
Hemopexin (Hx) is another plasma glycoprotein able to bind heme with high affinity. Hx
sequesters heme in an inert, non-toxic form and transports it to the liver for catabolism
and excretion. In the present review we discuss the components of physiologic Hb/heme
detoxification and their potential therapeutic application in a wide range of hemolytic
conditions.
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INTRODUCTION
Hemolysis with release of free hemoglobin (Hb) and heme occurs
in a wide range of disease states and clinical interventions, includ-
ing genetic and acquired anemias such as sickle cell disease,
burns, extracorporeal circulation and massive blood transfusion
(Schaer et al., 2013c). Additionally, chemical or recombinant
modified Hbs have been evaluated as oxygen therapeutics in sev-
eral disease states or when blood is not available (Silverman and
Weiskopf, 2009). The study of these therapeutic candidates has
also provided relevant information regarding the concentration-
dependent pathophysiology associated with extracellular Hb in
circulation and tissue compartments. Critical reviews provide
greater detail concerning their dose dependent toxicity (Buehler
et al., 2010).
The primary pathophysiologic effects associated with free
Hb/heme are acute hemodynamic instability and acute or chronic
tissue injury (Schaer et al., 2013c). The underlying biochem-
istry of these adverse effects appears to be related to the nitric
oxide and oxidant reactivity of free Hb and heme. The ability to
counteract extracellular Hb resulting from normal red blood cell
turnover andmild hemolysis is one function of haptoglobin (Hp),
an α2-sialoglycoprotein, which is the primary Hb-binding pro-
tein in plasma. Hb-bound Hp targets a specific cellular pathway
of clearance through the monocyte/macrophage surface recep-
tor CD163 (Kristiansen et al., 2001). Depending on the extent
and frequency of hemolysis, Hp may become depleted, render-
ing this pathway ineffective. Previous reports from patients with
sickle cell disease, spherocytosis, autoimmune hemolytic anemia,
erythropoietic protoporphyria and pyruvate kinase deficiency
suggest that Hp depletion in plasma occurs prior to the decline of
hemopexin (Hx) concentrations (Muller-Eberhard et al., 1968).
The disease related consumption of the plasma Hp pool during
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hemolysis makes Hp a specific clinical marker for intravascular
hemolysis (Kormoczi et al., 2006).
Heme released following oxidation of Hb to met-Hb or from
heme saturated hepatocytes is bound by albumin and rapidly
transferred to Hx, the plasma protein with the highest bind-
ing affinity for heme. Hx is another glycoprotein produced by
the liver with a plasma concentration of 1–2mg/ml (Muller-
Eberhard et al., 1968). Hx prevents heme’s pro-oxidant and
pro-inflammatory effects and promotes its detoxification, partic-
ularly when Hp concentrations are low or depleted in cases of
severe or prolonged hemolysis. Both Hp and Hx are acute-phase
proteins, induced during infection and inflammatory states in
order to minimize tissue injury and facilitate tissue repair.
The present review will describe the primary mechanisms
by which Hp and Hx prevent Hb/heme toxicity prior to
monocyte/macrophage-hepatocyte clearance, critically evaluate
the difference in genetic phenotype function and describe the
rationale for exogenous Hp and Hx as therapeutic proteins for
use in hemolytic disease states.
MECHANISMS BY WHICH Hp AND Hx PROTECT AGAINST
Hb/heme TOXICITY
Mechanistic research on the in vitro and in vivo function of Hp
and Hx has suggested well defined mechanisms of protection
(Schaer et al., 2013c). The best-characterized function of Hp is
intravascular sequestration of extracellular Hb following forma-
tion of large Hb-Hp protein complexes, a process that prevents
extravasation of free Hb into tissues. This effect is particularly
evident in the kidneys where oxidative reactions at the heme moi-
ety of Hb lead to globin deposition (hyaline casts), iron overload,
lipid peroxidation and renal tubular injury (Qian et al., 2010;
Ballarin et al., 2011; Billings et al., 2011) (Figure 1). Similarly, by
sequestering heme within a protein complex, Hx prevents heme’s
ability to intercalate into cell membranes and plasma lipopro-
teins, where it participates in reactions with organic peroxides,
the result of which is the generation of free radicals in local-
ized tissue spaces followed by lipid, protein and DNA oxidation.
Additionally, Hx blocks heme activation of immune receptors and
vascular inflammatory processes (Belcher et al., 2014). The com-
bined antioxidant and Hb/heme binding characteristics of Hp
and Hx allow Hb-Hp and heme-Hx complexes to circulate in
the blood in a less toxic form until they can be cleared by their
respective scavenger receptors. In the following sections, Hp and
Hx will be discussed with an emphasis on tissue protection from
the deleterious effects of extracellular Hb and heme.
Hp AND Hx SEQUESTER EXTRACELLULAR Hb/heme WITHIN THE
PLASMA COMPARTMENT UNTIL CELLULAR CLEARANCE
Within red blood cells (RBCs), Hb exists as a tetrameric heme
containing protein with a molecular weight of 64 kD. Following
release from RBCs during intravascular hemolysis, extracellular
Hb is in a dynamic tetramer ↔ dimer equilibrium (Ackers and
Halvorson, 1974). The dimer fraction of Hb is favored by low
Hb concentration and an oxygenated Hb (Fe2+) state. The 32-kD
Hb dimer readily passes through the glomerulus—if not bound
by Hp—and is rapidly cleared by the kidneys (Murray et al.,
1961; Andersen et al., 1966; Boretti et al., 2009). Renal filtra-
tion is therefore a primary route of clearance for extracellular Hb
following Hp depletion. In guinea pigs and dogs, we have pre-
viously characterized plasma clearance of extracellular Hb with
a circulatory half-life of approximately 10–60min (Boretti et al.,
2009, 2014). This is consistent with earlier findings using radio-
labeled Hb in rabbit and dog (Bunn et al., 1969). Hb can also
be filtered into the lymphatic system after intravascular injec-
tion, and translocates across intact endothelial monolayers both
in vitro and in vivo (Nakai et al., 1998; Faivre-Fiorina et al.,
1999; Matheson et al., 2000). The mechanisms underlying this
“translocation/extravasation” phenomenon remain unclear, but
may involve active transport mechanisms—for example, through
the caveolar system, which is also responsible for the controlled
transendothelial transport of other plasma proteins such as albu-
min (Faivre-Fiorina et al., 1999; Komarova and Malik, 2010).
Within the plasma compartment, the abundance of anti-
oxidants (i.e., ascorbic acid and urate) stabilizes Hb in a reduced
state (Butt et al., 2010). This physiologic function of plasma
makes it less likely for Hb to participate in oxidative reactions
that lead to rapid met-Hb formation and release of free heme.
However, once dimerization of Hb occurs, autoxidation of dimers
proceeds rapidly with a rate constant (kox = 0.24 h−1) 16-fold
faster than tetrameric Hb (kox = 0.015 h−1) (Griffon et al., 1998).
Furthermore, after translocation into the extravascular space,
Hb may encounter much harsher oxidative conditions than in
plasma. This may be particularly true in diseased and inflamed
tissues or after an ischemic insult when oxidants accumulate
and an acidic pH is created in local tissue sites. A disconnect
of intravascular and extravascular Hb oxidation was observed
in animal models of intravascular hemolysis or following infu-
sion of ferrous (Fe2+) Hb. While oxidized ferric (Fe3+) Hb
usually remains below the level of detection in plasma, a large
fraction of excreted Hb ultimately appears in the urine in the
oxidized ferric state (Boretti et al., 2009). This observation could
be extrapolated to other tissues, such as the vascular wall, where
Hb(Fe3+) may accumulate. The large Hb-Hp complex cannot be
filtered by the kidney and in vitro translocation across endothe-
lial monolayers is almost completely blocked (Lipiski et al., 2013).
The most evident protective function of Hp is therefore the
sequestration of extracellular Hb within the antioxidant rich
plasma compartment (Figure 2). Following binding, Hp lim-
its Hb’s access to susceptible environments where heme release,
oxidative processes and NO-consuming reactions are much more
likely to occur and may finally lead to the sequelae of Hb tox-
icity, such as renal failure and vascular injury (Gladwin et al.,
2012).
A similar sequestering function is observed with Hx, which
is capable of controlling the reactivity of free heme following
orientation into Hx’s “heme pockets.” By scavenging free heme,
Hx prevents heme-mediated oxidative reactions with lipids, pro-
teins, nucleic acids and other biological molecules. Along with
Hx, several plasma proteins are able to bind heme, includ-
ing albumin, lipoproteins, α1-microglobulin, but none of these
proteins can efficiently prevent heme intercalation into lipid
membranes or block heme’s pro-oxidant and pro-inflammatory
effects.
Frontiers in Physiology | Oxidant Physiology October 2014 | Volume 5 | Article 415 | 2
Schaer et al. Haptoglobin, hemopexin, and associated pathways
FIGURE 1 | Sequence of renal plasma clearance of hemoglobin:
The sequence represents sustained intravascular hemolysis in a
guinea pig model. The red color of Hb in plasma during hemolysis
suggests ferrous Hb accumulation. In the presence of haptoglobin
free Hb is sequestrated within the Hb-Hp complex. Processes of
Hb-Hp clearance are saturated during massive hemolysis and the
complex remains in circulation for an extended period of time, leading
to the brownish color or ferric heme in bound Hb dimers, which is
a result of auto-oxidation or reaction with NO or other oxidants in
plasma. Free hemoglobin readily dissociates into dimers in plasma,
leading to extensive glomerular filtration, which is blocked by Hp.
The filtration of Hb leads to renal tubule iron deposition (brown) and
hemoglobinuria. This is not observed in control animals or when Hp
is administered and Hb remains sequestered in the Hb-Hp complex.
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FIGURE 2 | Diastolic (A) and systolic (B) systemic arterial blood
pressure response after bolus infusion of free Hb followed by a bolus
infusion of purified human Hp in guinea pigs. (C) HPLC analysis of
guinea pig plasma after infusion of free Hb followed by Hp. The traces
show free Hb co-eluting with an Hb standard (red). The Hb-Hp complex
has a larger molecular weight, as indicated by the earlier elution time. The
Hb-Hp complex has a long circulation half-life with detectable levels up to
50 h after infusion in this species. (D) NO reactions with free Hb in the
vascular wall. Ferrous Hb (Fe2+) can react with the vasodilator NO via two
reactions: (1) NO dioxygenation of oxy-Hb that generates nitrate (NO−3 ) and
ferric Hb (Fe3+), and (2) iron nitrosylation of deoxy-Hb that occurs by direct
iron binding of NO to non-liganded ferrous Hb (Fe2+). Both reactions lead
to depletion of NO and explain the acute vasoactivity of extracellular Hb,
which is attenuated by Hp.
Hp AND Hx PROMOTE FREE Hb AND HEME CLEARANCE VIA RECEPTOR
TARGETED PATHWAYS
Haptoglobin
Hb toxicity largely depends on the rate of hemolysis, tissue oxi-
dant status and clearance capacity. In this network, Hp acts in
concert with the plasma’s small molecular reducing agents that
maintain Hb in a reduced, less reactive ferrous (Fe2+) oxidation
state (Buehler et al., 2007).
In addition to keeping Hb within the antioxidant environment
of plasma, Hp plays an essential role in the clearance of Hb and
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metabolic detoxification of heme (Figure 3). In humans, the scav-
enger receptor CD163, previously assigned as the macrophage
scavenger receptor M130 (Law et al., 1993), has been identified
as an endocytosis receptor for Hb-Hp complexes (Kristiansen
et al., 2001). CD163 is exclusively expressed by cells of the
monocyte-macrophage lineage, with particularly high expression
levels in red pulp macrophages of the spleen and liver Kupffer
cells (Zwadlo et al., 1987; Bachli et al., 2006). Within the Hb-
Hp complex, a high-affinity binding epitope has been identified
within the interface region of the Hp β-chain and the Hb α-chain
(Madsen et al., 2004; Andersen et al., 2012). Tetrameric Hb can
also bind to and is internalized by CD163 in the absence of Hp
(Schaer et al., 2006; Buehler et al., 2008). It is unknown whether
this lower affinity interaction involves similar regions within Hb
and CD163, or whether separate binding structures have inde-
pendently evolved for Hb and the Hb-Hp complex, respectively
(Buehler et al., 2008). Experimental evidence suggests that other
Hb andHb-Hp clearance pathways exist in addition to the CD163
scavenger receptor, and that efficient non-renal Hb clearance
mechanisms may be active in the absence of Hp (Murray et al.,
1961; Schaer et al., 2006; Etzerodt et al., 2013). However, the
nature of these mechanisms requires further studies to be more
thoroughly understood.
Inflammatory and anti-inflammatory processes modulate the
activity of the Hb-Hp scavenger pathway at multiple levels.
Systemic inflammation, particularly if it involves the inter-
leukin (IL)-6 effector pathway, increases expression of Hp in
the liver and many parenchymal and non-parenchymal cells.
In many species, Hp is one of the most extensively respond-
ing acute-phase plasma proteins. IL-6 has also been reported
to enhance expression of CD163 on macrophages, suggesting
that enhanced Hb sequestration and clearance capacity are gen-
eral adaptive responses to infection and tissue injury (Buechler
et al., 2000). Intriguingly, however, some inflammatory medi-
ators, such as endotoxin and other Toll-like receptor (TLR)
agonists or tumor necrosis factor-α (TNF-α) trigger protease-
mediated shedding of CD163 from the cell surface of mono-
cytes and macrophages (Droste et al., 1999; Hintz et al., 2002;
Moller et al., 2002; Weaver et al., 2006; Etzerodt et al., 2010).
This shedding acutely blocks clearance of Hb-Hp complexes by
monocytes (Schaer et al., 2007). High levels of soluble CD163
are consequently found in patients with sepsis or more specific
macrophage activation syndromes (Schaer et al., 2005; Moller
et al., 2006). The physiologic role of this process is unknown,
but it implies that complex regulatory mechanisms control Hb
detoxification and cellular exposure. Additionally, sCD163 may
itself contribute the oxidative detoxification of extracellular Hb
and Fcγ-receptor-mediated endocytosis of sCD163-Hb-IgG com-
plexes by monocytes/macrophages, and endothelial cells have
been proposed to be an alternative route for Hb clearance
(Subramanian et al., 2013).
Of special consideration is the regulation of the Hb clearance
system by anti-inflammatory glucocorticoids. In global proteome
and transcriptome exploration studies, CD163 was found to be
one of the principal glucocorticoid-induced genes in human and
mouse macrophages, and patients treated with high-dose pulse
glucocorticoids had a significantly enhanced Hb-Hp clearance
capacity of their peripheral blood monocytes (Schaer et al.,
2001, 2002; Vallelian et al., 2010). Glucocorticoids also act as a
transcriptional (co-)activator on Hp synthesis in many species,
including human (Marinkovic and Baumann, 1990). In a dog
model, a glucocorticoid-supported high Hp level was completely
protective against hemoglobinuria and hypertension during an
8-h infusion of free Hb (Boretti et al., 2009). Cumulatively,
inflammation and glucocorticoids appear to enhance tolerance
against extracellular Hb. In contrast, other drugs such as the
antimalarial chloroquine can negatively affect Hb/heme detox-
ification in macrophages and potentially enhance free Hb tox-
icity (Schaer et al., 2013b). The potential clinical relevance of
these observations—for example, for the treatment of hemolytic
anemias—remains to be resolved.
Hemopexin
The heme scavenging function of Hx primarily attenuates heme
toxicity on the vascular endothelium (Vinchi et al., 2013). While
heme easily enters into endothelial cells when bound to albu-
min, this translocation is completely blocked in the presence of
Hx. Heme sequestration within the Hx complex further ensures
protection against heme-driven oxidative processes in the extra-
cellular space and it prevents heme-triggered inflammation and
adhesion molecule expression.
In vivo, the heme-Hx complex is primarily cleared by hepa-
tocytes via receptor-mediated endocytosis (Vinchi et al., 2013).
To date, the only known heme-Hx complex receptor is the
LDL receptor-related protein 1 (LRP 1), a multi-ligand scav-
enger receptor (Hvidberg et al., 2005). In addition to hepato-
cytes, LRP1 is expressed on several other cell types, including
macrophages, neurons, and syncytiotrophoblasts. The role of
these LRP1 expressing cell types and the possible contribution of
alternative receptors in heme-Hx complex clearance remain to be
studied.
Some studies have suggested that Hx could be recycled as an
intact molecule to the extracellular milieu. However, Hvidberg
et al., have shown that most Hx is degraded in lysosomes
(Hvidberg et al., 2005). This agrees with the observation that
plasma Hx level usually deplete in disorders associated with free
heme exposures in both humans and mice.
Hp AND Hx SUPPORT LOCAL NO HOMEOSTASIS
Depletion of NO, which occurs when the gaseous vasodilator
reacts with Hb, explains the acute vasoactivity of extracellular
Hb, which is characterized by an acute systemic and, to some
extent, pulmonary hypertensive response (Figure 2) (Doherty
et al., 1998; Reiter et al., 2002; Gladwin et al., 2004; Olson et al.,
2004; Minneci et al., 2005). In experimental animals, consistent
acute hypertensive responses can be observed at extracellular Hb
levels exceeding approximately 40μM (heme). The observation
that infusion of an Hb-Hp complex lacks the vasoactivity of an
equimolar quantity of extracellular Hb has initially suggested that
Hp may interfere with Hb’s reactions with NO. However, when
the NO reactivity of the Hb-Hp complex was measured in vitro
or in animal plasma, no differences in NO-driven heme oxidation
and/or NO consumption were found between free Hb and the
Hb-Hp complex, respectively (Boretti et al., 2009). Additionally,
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FIGURE 3 | Summary of intravascular/extravascular Hb/heme clearance
and cellular/tissue distribution. The main components of the Hb/heme
detoxification system are haptoglobin (Hp), which sequesters Hb in the
oxidatively protected Hb-Hp complex and hemopexin (Hx). The Hb-Hp
complex is cleared and metabolized by CD163+ macrophages. Alternatively,
during more severe hemolysis, free heme—after release from ferric Hb—can
be detoxified by the hemopexin (Hx) rescue pathway. In all scenarios heme is
finally detoxified by the heme oxygenases, which provide free iron for export
by ferroportin or, alternatively, storage in the ferritin complex. The physiologic
clearance and detoxification organs for Hb/heme are the liver and spleen,
respectively, while the primary targets of Hb/heme toxic activities are the
vascular endothelium and the kidney.
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Hb-triggered changes in NO metabolite plasma concentrations
were not attenuated by Hp treatment at a dose that com-
pletely suppressed Hb’s hypertensive response (Baek et al., 2012).
Therefore, it was speculated that Hp supports local NO bioavail-
ability by keeping the small Hb molecule away from sites of NO
production or NO effector functions. Such vulnerable anatomic
sites might be the endothelial caveolar system, which represents
the primary localization of endothelial NO synthase, the suben-
dothelial space, or the NO responsive contractile smooth muscle
cell layers within the wall of arterial resistance vessels (Buehler
et al., 2010).
Hx also appears to support vascular NO homeostasis as
demonstrated by studies in heme-overloaded Hx-null mice and
mouse models of hemolytic disorders (Chiabrando et al., 2014).
It is also likely that the beneficial effect of Hx on NO bioavail-
ability is due to heme sequestration away from sites of NO
production. Several scenarios could contribute to heme-driven
reduction of NO availability. The increased production of reactive
oxygen species (ROS) induced by heme may promote NO con-
sumption and formation of peroxynitrite (ONOO-) through the
reaction of NOwith superoxide (O·−2 ). Additionally, NO synthase
(NOS), may be uncoupled due to oxidation of the essential cofac-
tor BH4, thus leading to the generation of O·−2 in place of NO.
Accumulation of ONOO-may further contribute to the reduction
of NOS activity and the disruption of the NOS dimer.
In summary, although a sparing effect of Hp and Hx on local
vascular NO homeostasis is strongly supported, an experimental
proof of this concept is still warranted.
Hp CONTROLS OXIDATIVE REACTIONS OF Hb
Increased tissue concentrations of peroxides [i.e., hydrogen per-
oxide (H2O2) or lipid peroxides] occur in many disease states,
particularly within the context of inflammatory reactions and
during cycles of ischemia followed by reperfusion (Niethammer
et al., 2009). The biochemical reactions of Hb with peroxides have
been extensively studied in vitro and can be summarized as fol-
lows: deoxy-Hb reacts with H2O2 via the following steps: (1) oxo-
ferryl Hb [Hb(Fe4+ = O)] generation, (2) ferric Hb [Hb(Fe3+)]
generation, and (3) protein radical generation [·Hb(Fe4+ = O)]
(Boutaud et al., 2010).
Hb(Fe2+) + H2O2 → Hb(Fe4+=O) + H2O (1)
Hb(Fe4+=O) + H+ → Hb(Fe3+)OH− (2)
Hb(Fe3+) + H2O2 → ·Hb(Fe4+=O) + H2O (3)
The globin chain free radical shown in reaction 3 can partic-
ipate in localized amino acid oxidations within Hb (“intrinsic
reactions”) or it can transfer to susceptible external molecules
such as lipoproteins (“extrinsic reactions”). During the “intrin-
sic” free radical reactions within Hb, a defined peptide hotspot
that is located at the α-globin/β-globin interface becomes the
primary site where amino acid oxidation occurs. Among these
amino acids is the highly susceptible β-chain Cys93, which can
be oxidized to cysteic acid, as well as the α-chain Tyr42, which
appears to be an important radical hub within Hb (Jia et al.,
2007; Reeder et al., 2008; Pimenova et al., 2010). The cumula-
tive result of these oxidative processes becomes apparent as an
unfolding, intermolecular crosslinking and progressive degrada-
tion of the Hb molecule (Jia et al., 2007; Vallelian et al., 2008).
The oxidized protein can escape clearance by the Hp-CD163 scav-
enger pathway, and it appears that someHb degradation products
may eventually have direct pro-inflammatory and cytotoxic activ-
ities (Buehler et al., 2009; Schaer et al., 2013a). The result of the
“extrinsic” radical reactions may be the generation of oxidized
lipoproteins, damage to other (non-Hb) proteins and modifica-
tion of cell membrane components (Miller et al., 1997; Schaer
et al., 2013a). Hp binding does not reduce the primary reactivity
of Hb with peroxides, a reaction that is generally measured as the
initial change in the heme-iron oxidation states (i.e., oxidation of
Fe2+ → Fe3+ → Fe4+) during the peroxidative reaction sequence.
However, Hp binding limits secondary reactions of these com-
pounds with internal (i.e., globin amino acids) and/or external
substrates (Miller et al., 1997; Cooper et al., 2013).
The structural basis of this protection is not yet understood.
Hp complex formation may physically limit the transfer of rad-
icals located on the surface of Hb toward external acceptor
molecules. Additionally, Hp may limit direct heme pocket access
for external substrates. Furthermore, Hb dimerization that is
forced by Hb-Hp complex formation may interfere with intra-
molecular free radical translocation pathways that normally exist
across the Hb dimer interface. Lastly, it has been proposed that
Hp may function as a suicidal free radical scavenger within the
complex (Pimenova et al., 2010). In vitro, the primary result of
this oxidative protection becomes apparent as a stabilization of
Hb’s protein structure (Pimenova et al., 2010).
Hp PREVENTS HEME RELEASE FROM Hb
Heme is an extremely hydrophobic compound that cannot persist
as a monomeric soluble molecule under physiologic pH condi-
tions. The term “free heme” is therefore a misnomer, which in fact
refers to heme that is not stably located within the heme pocket
of a classic heme protein such as Hb or myoglobin. Instead, heme
can readily be transferred from ferric (but not from ferrous) Hb to
low-affinity heme acceptors (Bunn and Jandl, 1968; Gattoni et al.,
1996). The most extensively studied low-affinity heme acceptors
are lipoproteins and albumin; however, the group of low-affinity
heme acceptors likely involves a very diverse group of soluble and
membrane-based proteins and lipids. In the case of lipoproteins,
the transferred heme can trigger a lipid-peroxidation cascade,
which ultimately results in structural modification of the parti-
cle (Balla et al., 1991). Oxidized lipoproteins are cytotoxic and
represent one of the principal mediators of Hb toxicity (Nagy
et al., 2010; Schaer et al., 2013a). Less understood effects of heme
transfer (or “free heme”) are its direct cytotoxic and inflammatory
effects (Balla et al., 1993; Belcher et al., 2000, 2003; Wagener et al.,
2001; Jeney et al., 2002; Larsen et al., 2010; Fortes et al., 2012).
Proposed mechanisms involve stimulation of Toll-like receptors,
such as the endotoxin receptor TLR-4 and inhibition of the pro-
teasome, among others (Figueiredo et al., 2007; Lin et al., 2012a;
Vallelian et al., 2014).
It is in this context that the fourth known protective activ-
ity of Hp appears: the prevention of heme release from ferric
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(Fe3+) Hb (Bunn and Jandl, 1968; Lipiski et al., 2013; Mollan
et al., 2014). We have previously learned that ferric Hb (Fe3+)—
the substrate for heme transfer—does not usually accumulate
in plasma, even under severe hemolytic conditions (Baek et al.,
2012). It is therefore unlikely that heme transfer from Hb is a rel-
evant process that occurs during hemolysis within the plasma.
However, unlike extracellular Hb, the Hb-Hp complex has a
slower and saturable clearance, which allows ferric (Fe3+) Hb-
Hp to accumulate and to reach significant plasma concentrations.
In a hemolysis model in guinea pigs, we detected up to 50% of
ferric Hb-Hp 24 h after infusion of an Hp bolus for treatment
of severe blood transfusion-associated hemolysis. Conceptually,
the Hb-Hp complex in plasma may therefore be better compared
with a polymerized Hb such as a hemoglobin-based oxygen car-
rier (HBOC). The intentionally slow clearance rates of HBOCs
also allow these substances for significant accumulation of fer-
ric species in vivo. Following infusion of most HBOCs there is
no barrier against heme release and the oxidative damage that
is associated with heme loss may be a significant component of
vascular toxicity that accompanies administration of these ther-
apeutic candidates (Natanson et al., 2008). As an evolutionary
hypothesis, it is possible that the protective strategy of Hb seques-
tration within the plasma compartment was only achievable in
combination with the sophisticated heme retention and oxida-
tion control capacities of Hp. Only these functions may allow
the large Hb-Hp complex to circulate in a less toxic form until
cleared. Heme retention and oxidative stability may therefore dis-
criminate the Hb-Hp complex from the adverse event profile of
some HBOCs with comparable molecular size and long intravas-
cular retention times (Pimenova et al., 2009; Silverman et al.,
2009).
Hx BLOCKS INTERACTIONS OF FREE HEME WITH BIOLOGICAL
MOLECULES
Hx has the highest binding affinity for heme (Kd < 10−13 M).
Hx sequesters heme in an oxidatively inert conformation in a
complex with a 1:1 stoichiometry, until it is cleared by the liver.
Heme transfer to more reactive biomolecules is therefore sup-
pressed by Hx. Accordingly, heme-overloaded Hx-null mice show
increased oxidative stress in blood vessels, endothelial activa-
tion, enhanced inflammation and decreased NO bioavailability
(Vinchi et al., 2013). Moreover, Hx-null mice display defective
heme accumulation and catabolism in hepatocytes and reduced
heme excretion in the bile (Tolosano et al., 1999; Vinchi et al.,
2008, 2013).
The work of Belcher et al. (2014) has provided additional
insight into how heme sequestration within the heme-Hx com-
plex could attenuate heme-triggered inflammation. Heme is a
weak activator of TLR4 and in endothelial cells heme-mediated
TLR4 activation promotes Weibel-Palade body (WPB) degranu-
lation, enhanced expression of adhesion molecules and activation
of NF-κB (Belcher et al., 2014). The heme-triggered activation
of the TLR4 pathway is blocked by Hx. By similar mechanisms,
Hp and Hx may interrupt the synergistic pro-inflammatory and
toxic activities of Hb that occur in synergy with HMGB1 and
LPS, respectively (Liang et al., 2009; Baek et al., 2014). Other
anti-inflammatory effects of Hx may also represent a direct
macrophage suppressor effect, which is independent of Hb/heme-
triggered signaling (Lin et al., 2012b).
HAPTOGLOBIN AND HEMOPEXIN IN PATHOLOGY AND
DRUG DEVELOPMENT
CARDIOVASCULAR DISEASES
Due to its unique anatomic location, the vascular wall appears
to be the principal target of free Hb and heme exposure dur-
ing hemolysis. The diverse Hb/heme-triggered disease processes
(i.e., NO consumption, lipid peroxidative processes) are there-
fore likely to modulate pathologies of the cardiovascular sys-
tem such as atherosclerosis or typical vascular complications of
hemolytic anemias. Oxidized lipoproteins are an established pro-
moter of atherosclerosis and both Hb and heme can promote
LDL oxidation (Balla et al., 1991; Belcher et al., 2010; Nagy et al.,
2010). Likewise, free heme appears to be an endogenous trig-
ger of endothelium and monocyte/macrophage inflammation,
which are both essential in the progression of atherosclerotic
lesions (Belcher et al., 2014). Furthermore, heme that is released
during microhemorrhage in the vascular wall appears to be a fun-
damental modulator of the resident macrophage phenotype in
atherosclerotic plaques (Boyle et al., 2009, 2012; Kaempfer et al.,
2011; Finn et al., 2012). However, despite all this biochemical and
cell biologic evidence there is so far no direct experimental or
epidemiologic proof that chronic hemolysis or microhemorrhage
related Hb release into the vascular wall could directly aggravate
atherosclerosis. Accordingly, we do not know whether substitu-
tion of Hp or Hx at supra-physiologic levels could attenuate this
process. More evidence supports a direct contribution of Hb and
heme-triggered reactions to the cardiovascular complication of
sickle cell disease, primarily in relation to pulmonary hyperten-
sion and the acute chest syndrome. Nitric oxide consumption by
free Hb and heme-triggered endothelial inflammatory activation
are the principal pathophysiologic components (Rother et al.,
2005; Ghosh et al., 2013; Belcher et al., 2014).
Hp POLYMORPHISM AND CARDIOVASCULAR DISEASE ASSOCIATIONS
In humans, an Hp gene polymorphism exists that determines the
three major phenotypes: 1-1, 2-1, and 2-2 (Levy et al., 2010).
As a result of a partial intragenic duplication within the Hb α-
chain coding region on chromosome 16 (16q22.2), Hp α-chain
2, as opposed to Hp α-chain 1, has two cysteines for disulfide
bonding with two other α-chains. Therefore, Hp 2-2 is secreted
as a heterogeneous mixture of Hp αβ-chain polymers, whereas
the Hp 1-1 phenotype is produced as a homogeneous αβ-dimer.
Phenotype 2-1 is a mixed phenotype composed of a range of
dimers and polymers. The phenotype distribution varies accord-
ing to ethnicity; however, in the Western world, it approaches
15% for Hp 1-1, 50% for Hp 2-1, and 35% for Hp 2-2 (Langlois
and Delanghe, 1996). The crystal structure of the Hb-Hp complex
confirmed earlier biochemical studies predicting that only the
non-polymorphic β-chain subunit of Hp interacts with bound
Hb αβ-dimer, although no functional role of the α-chain could be
inferred from these studies (Andersen et al., 2012). Therefore, per
milligram, Hp protein, Hb binding and the physiologic “neutral-
ization” capacity of the three phenotypes should be comparable.
The assumption of equal binding has also been confirmed by
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independent studies in human plasma and with purified Hb-Hp
complexes (Delanghe et al., 2000; Lipiski et al., 2013).
In the past, multiple functions of Hp, such as its anti-oxidative
and CD163 adaptor functions, have been reported to be phe-
notype dependent (Asleh et al., 2003, 2005; Levy et al., 2007).
Cumulatively, these studies implied that the Hp 2-2 pheno-
type might be dysfunctional compared to Hp 1-1, with less
protective capacity against Hb-triggered pathologies. However,
more recently, larger quantities of more standardized and better-
characterized Hp proteins became available for experimental
studies, including in vivo administration studies. These experi-
mental Hp products resulted from industrial efforts to develop
phenotype-specific therapeutic Hp products from pooled human
plasma. Comparative investigations of two Hp products with pre-
dominant Hp 1-1 or Hp 2-2 composition found no significant
differences in the intravascular sequestration or renal and vas-
cular short term protection provided by dimeric and multimeric
Hp phenotypes in a therapeutic setting of acute intravascular Hb
exposure in guinea pigs and dogs (Lipiski et al., 2013; Boretti
et al., 2014). Additionally, a range of biochemical studies examin-
ing oxidative Hb reactions, prevention of low-density lipoprotein
oxidation, and heme retention in the Hb-Hp complex provided
evidence of equal protective functions of the dimeric and multi-
meric phenotypes (Lipiski et al., 2013). Also, NO consumption
appears to be identical with the Hb:Hp 1-1 and 2-2 complexes
(Azarov et al., 2008; Lipiski et al., 2013).
Epidemiologic studies have also found controversial associa-
tions of Hp genotypes with the prevalence and clinical sequelae
of atherosclerosis in the general population and in specific patient
populations, particularly those with diabetes mellitus. However,
more stratified analysis of several large observational studies now
convincingly revealed that the Hp 2-2 genotype/phenotype is
associated with increased relative risk of coronary artery disease
of up to 10-fold in diabetic patients with a glycosylated HbA1c >
6.5 (Cahill et al., 2013). Accompanying mechanistic studies have
found higher tissue iron accumulation, additional signs of oxida-
tive damage and a higher number of apoptotic macrophages
in aortic atherosclerotic plaques from patients with the Hp 2-2
genotype (Moreno et al., 2008; Purushothaman et al., 2012).
Thus, far, the pathophysiology underlying these associations
is unknown. According to studies discussed above, the primary
Hb detoxifying functions of Hp 1-1 and Hp 2-2 are comparable
and can therefore not easily explain the epidemiologic differences.
However, the biologic functions of Hp that have been investi-
gated so far are more representative of the short term protective
functions of Hp during acute hemolysis and may not fully reflect
longer term antioxidant or immune modulatory functions of the
protein that might be more relevant for chronic vascular disease
development.
Most epidemiologic studies of phenotype association with
cardiovascular disease have been controlled for overall popula-
tion heterogeneity and for established cardiovascular risk factors;
however, these studies were not systematically controlled for
differences in Hp plasma concentrations (Cahill et al., 2013).
Generally, individuals with the Hp 2-2 phenotype have lower
plasma Hp concentrations. Therefore, besides the postulated
phenotype dependent molecular functions of Hp, lower Hp
concentrations may have an additional impact on vascular dis-
ease development in individuals with the Hp 2-2 phenotype (Cid
et al., 1993; Shen et al., 2012).
The controversial findings related to Hp phenotype-specific
functions and associated disease state risks should certainly stim-
ulate more extensive investigations. However, it now appears that,
for therapeutic considerations, the Hp phenotype selection of
a product will likely not be a primary determinant of clinical
success (Lipiski et al., 2013).
DISEASE RISK AND Hx
A genetic Hx polymorphism has been reported in populations
of African ancestry (Kamboh et al., 1993). The biological sig-
nificance of this polymorphism in hemolytic disorders is merely
speculative.
The only available data suggesting a strong association between
plasma Hx level and disease risk come from studies evaluating
the mouse model of Hx deficiency (Tolosano et al., 1999). Several
studies reported a higher susceptibility of Hx-null mice to hemol-
ysis triggered organ damage and heme-driven vascular injury,
as discussed below. In other diseases, the impact of Hx has not
been directly related to its function as a heme scavenger, likely
due to the technical difficulties in quantifying small amounts of
“free” heme or possibly due to heme-independent functions of
Hx. One such example is related to a regulatory function of Hx
in neuroinflammation. Hx deficient mice are more susceptible to
the development of experimental autoimmune encephalomyeli-
tis (EAE), the murine model of multiple sclerosis (Rolla et al.,
2013). In mice, Hx deficiency favors the differentiation of naïve
CD4+ T cells toward Th17 lineage and enhances the stabiliza-
tion and expansion of memory Th17 cells by IL-23. This is due
to a higher disposition of naïve T cells to differentiate toward the
Th17 lineage and to a higher production of Th17 differentiating
cytokines IL-6 and IL-23 by APCs. These data indicate that Hx
may have a negative regulatory role in Th17-mediated inflamma-
tion. Interestingly, Hp-null mice subjected to EAE also develop an
exacerbated disease and display an increased expression of inflam-
matory cytokines in the central nervous system, suggesting that
Hp and Hx share some anti-inflammatory effects (Galicia et al.,
2009). The potential role of the common Hb-heme axis remains
to be established.
PRE-CLINICAL STUDIES OF SCAVENGER PROTEIN THERAPEUTICS
Mouse models of sickle cell disease have a phenotype of chronic
heme-driven endothelial activation and dysfunction that could be
recovered by repeated Hx administration (Vinchi et al., 2013).
These findings highlight a causative role of the free Hb-heme
axis in SCD associated vasculopathy. Acute increases in plasma
Hb or extracellular heme concentrations can trigger acute vasco-
occlusion as well as the acute chest syndrome in SCD mice. Two
independent studies have shown that both vaso-occlusion and the
acute chest syndrome can be prevented by the infusion of Hp or
Hx, respectively (Ghosh et al., 2013; Belcher et al., 2014).
Hemolysis has also been recognized to exacerbate some renal
and vascular complications related to the transfusion of stored
red blood cells. Retrospective clinical observation studies sug-
gested a link between the storage duration of red blood cells and
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the incidence of cardiovascular complications such as myocar-
dial infarction, stroke and death. One component of the so-called
red blood cell storage lesion is an increased RBC fragility, which
may lead to hemolysis post-transfusion. In a guinea pig transfu-
sion model, increased fragility of older RBC could be linked to
increased hemolysis in the post-transfusion period, appearance of
free Hb in the circulation and Hb-triggered injury in the kidney
and vasculature. All these pathologic changes could be prevented
by Hp treatment at the time of old blood transfusion (Baek et al.,
2012; Lipiski et al., 2013).
Hemolysis with increased free Hb/heme levels and accompa-
nying Hp/Hx depletion can be observed in some patients with
severe sepsis. In a mouse sepsis model, Hx administration signif-
icantly reduced organ injury and mortality (Larsen et al., 2010),
presumably by blocking free heme-mediated oxidative processes
and inflammation. In contrast, other mouse studies provided evi-
dence that Hx could even accelerate uncontrolled infection by a
poorly defined activity that impairs leukocyte recruitment to the
focus of primary infection (Spiller et al., 2011). Observational
studies in human patients provided evidence for a positive asso-
ciation of mortality with free Hb release in adults with sepsis
(Janz et al., 2013). In this patient cohort, preserved plasma Hp
concentrations were significantly correlated with reduced mor-
tality. Whether these data could point to a causative role of free
Hb/heme in the progression of human sepsis remains specula-
tive and further laboratory research and better-controlled clinical
studies are needed to resolve the role of the Hb/heme-Hp/Hx axis
in the control of severe infection and sepsis.
POTENTIAL CLINICAL USES OF PLASMA-DERIVED HUMAN Hp AND Hx
The rationale for the use of Hp and Hx as therapeutic agents
is based on the idea that they act by scavenging circulating Hb
and heme, with particular relevance to pathological conditions
associated with hemolysis. Central to this concept is the notion
that acute and chronic hemolytic conditions are characterized
by depletion of the Hb and heme scavengers. Pre-clinical proof-
of-concept animal models have demonstrated that Hp and Hx
effectively attenuate Hb- and heme-induced vascular and renal
pathologies. Based on these preliminary observations, it would
appear rational to develop Hp and Hx for therapeutic use (Boretti
et al., 2009; Dalton and Podmore, 2011). Plasma-purified Hp has
been marketed in Japan since 1985 with primary indications for
use in conjunction with extracorporeal circulation, massive trans-
fusion and thermal injury (Schaer et al., 2013c). The primary
therapeutic effect in these disease states is protection of the kid-
neys from Hb-induced toxicity (Hashimoto et al., 1993). Dosing
approaches to minimize overall renal exposure to Hb in medi-
cally compromised patients are described in a few case reports
(Homann et al., 1977; Tanaka et al., 1991; Imaizumi et al., 1994).
However, the primary dosing strategy employed in these stud-
ies is consistent with a dose-to-effect approach, whereby the Hp
dose is increased until amelioration of hemoglobinuria occurs.
The Japanese medical communities’ use of Hp encompasses a
wide range of hemolytic events in approved and off-label disease
states in which hemolysis occurs. A new therapeutic protein being
considered for approval in the United States and European mar-
kets would require safety and efficacy trials in a specific disease
state with measurable efficacy end points. For example, in the cir-
cumstance of treating a chronic hemolytic anemia, such as sickle
cell disease, with repeated Hp and/or Hx doses, a measurable
outcome such as significant reduction in vascular complications,
reduced hospitalization or duration of hospitalization may be
required. As a result, selection of the appropriate disease state(s)
to demonstrate measurable improvements in morbidity remains
a critical and challenging decision for the drug development pro-
cess. Pre-clinical studies are still ongoing with the aim of better
defining the common and protein-specific functions of Hp and
Hx, their disease specific modulatory functions and potential off-
target effects. This research may further support well-designed
clinical trials translating the protective effects of heme scavengers
into clinical progress.
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